Better and safer cancer therapeutics first in line
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Update
LiPlasome Pharma at BIO-Europe 2008, Nano Tech 2009, BioMedical Asia 2009 and AACR 100th Annual Meeting 2009
LiPlasome Pharma is represented at conventions and other scientific events around the world...
Annual Report 2007
View or download Annual Report 2007, and learn more about LiPlasome Pharma, the lipid technology and...
LiPlasome Pharma welcomes new employees
Maria Ahlm Mattebjerg, Research Scientist - Sussie Røntorp, Clinical Operations Manager - Torben Elhauge, Documentation and QA Manager...
Creating a successful business with a new visual identity
The upcoming biotech company LiPlasome Pharma A/S is launching a new visual identity...
